Zobrazeno 1 - 4
of 4
pro vyhledávání: '"David Silva Moura"'
Polimorfismos dos alelos m1 e m2 do gene CYP1A1: Susceptibilidade genética para o cancro do pulmão
Autor:
Paula Mota, David Silva Moura, Maria Graça Vale, Henriqueta Coimbra, Lina Carvalho, Fernando Regateiro
Publikováno v:
Revista Portuguesa de Pneumologia, Vol 16, Iss 1, Pp 89-98 (2010)
Resumo: O cancro do pulmão é considerado uma doença relacionada com o meio ambiente, consequência da exposição a agentes mutagénicos, nomeadamente os presentes no fumo do tabaco. O gene CYP1A1 codifica a enzima aril hidrocarbonet
Externí odkaz:
https://doaj.org/article/3901b6c12e8c4ecc90e0ad25f702a8be
Autor:
Paula Mota, David Silva Moura, Maria Graça Vale, Henriqueta Coimbra, Lina Carvalho, Fernando Regateiro
Publikováno v:
Revista Portuguesa de Pneumologia, Vol 16, Iss 1, Pp 89-98 (2010)
Lung cancer is considered an environment-related disease that develops as a consequence of exposure to mutagenic agents, namely those present in tobacco. The CYP1A1 gene codifies the phase I enzyme aryl hydrocarbon hydroxilase (AHH) belonging to the
Externí odkaz:
https://doaj.org/article/7b4029a32fba40e6af4b02c2c333c0d6
Autor:
David Silva Moura, Jorge Zamora, Nadia Hindi, Maria Lopez-Alvarez, Serena Lacerenza, Giovanni Grignani, Javier Martinez-Trufero, Andres Redondo, Claudia Maria Valverde Morales, Silvia Stacchiotti, Antonio Lopez-Pousa, Antonio Gutierrez, Jose A. Lopez-Martin, Javier Martin Broto
Publikováno v:
Journal of Clinical Oncology. 40:11549-11549
11549 Background: Immunotherapy-based treatments had shown to be active in several solid tumors, including in selected subtypes of sarcomas. IMMUNOSARC (NCT03277924) is a phase Ib/II trial [from Spanish (GEIS) and Italian (ISG) sarcoma groups], that
Autor:
Javier Martin Broto, Jeronimo Martinez Garcia, David Silva Moura, Andres Redondo, Antonio Gutierrez, Antonio Lopez-Pousa, Javier Martinez-Trufero, Isabel Sevilla, Robert Diaz Beveridge, Maria Pilar Solis-Hernandez, Amancio Carnero, Marco Perez, David Marcilla, Jose A. Lopez-Martin, Antonio Casado Herraez, Rosa Maria Alvarez Alvarez, Josefina Cruz Jurado, Anna Estival-Gonzalez, Patricio Ledesma, Nadia Hindi
Publikováno v:
Journal of Clinical Oncology. 40:11511-11511
11511 Background: CDK4/6 inhibitors showed a favorable progression-free survival (PFS) in DD LPS, a sarcoma bearing 12q 13-15 amplicon that implies CDK4 amplification. The median PFS was 4 and 7 months (m) for palbociclib and abemaciclib, respectivel